Related Experiment Video
Updated: Jul 9, 2025
14:18
Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
Published on: October 13, 2023
1.8K
Targeting the Endothelin A Receptor in IgA Nephropathy
Donald E Kohan1, Jonathan Barratt2, Hiddo J L Heerspink3
1Division of Nephrology, University of Utah Health, Salt Lake City, Utah, USA.
Kidney International Reports
|November 29, 2023
Summary
Immunoglobulin A nephropathy (IgAN) is a common cause of kidney failure. Blocking the endothelin-A receptor (ETAR) shows promise in protecting kidneys and reducing protein in IgAN patients.
Area of Science:
- Nephrology
- Pharmacology
Background:
- Immunoglobulin A nephropathy (IgAN) is the leading cause of primary glomerulonephritis globally, often progressing to kidney failure.
- Emerging therapies for IgAN and chronic kidney disease (CKD) offer new hope for slowing renal decline.
Purpose of the Study:
- To review the evidence for endothelin-A receptor (ETAR) blockade in treating IgAN.
- To discuss the potential role of ETAR antagonists within the current and future therapeutic landscape for IgAN.
Main Methods:
- Review of preclinical studies demonstrating renoprotective effects of ETAR blockade in IgAN models.
- Analysis of clinical trial data showing proteinuria reduction with ETAR antagonists in IgAN patients.
Main Results:
- ETAR activation contributes to IgAN pathophysiology through vasoconstriction, inflammation, and fibrosis.
- ETAR blockade has demonstrated renoprotective benefits in experimental IgAN and reduced proteinuria in clinical studies.
Conclusions:
- Endothelin-A receptor blockade is a promising therapeutic strategy for IgAN.
- ETAR antagonists may play a significant role in managing IgAN alongside existing and novel treatments.
More Related Videos
Related Concept Videos
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
170
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
170
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
654
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
654
01:25Antihypertensive Drugs: Direct Renin Inhibitors
637
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
637
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
748
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
748
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
188
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
188